Experiments show that transferring a cancer cell's dysfunctional mitochondria—but not its nucleus—into a healthy cell is what induces cancer. This disruptive finding supports the view of cancer as a metabolic disease that can be targeted by starving its mitochondria of fuels like glucose.

Rion found that culturing stem cells in a lab to force division leads to rapid DNA damage, as cells are not designed for this artificial environment. This damage created inconsistent exosome products, making large-scale, uniform manufacturing from stem cells unfeasible and prompting a search for a more stable source.

Nobel Prize-winning research identified genes (Yamanaka factors) that revert specialized adult cells back into their embryonic, stem-cell state. This discovery proves cellular differentiation and aging are not irreversible, opening the door for regenerative therapies by "rebooting" cells to an earlier state.

Dr. Levin reframes cancer as a cognitive problem where the bioelectric "glue" binding cells into a collective fails. Cells lose their large-scale purpose and revert to an ancient, single-cell state. Restoring this electrical communication can normalize tumors without killing the cells, presenting a non-destructive therapeutic approach.

Modern clinical miracles like allogeneic stem cell transplants were not direct research goals. They were only made possible by decades of fundamental, government-funded science exploring abstract concepts like self vs. non-self immune recognition, highlighting the critical role of curiosity-driven basic research in medicine.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Many blood cancers are better understood as "regulatory problems" driven by epigenetic failures—the systems controlling which genes are turned on or off. This shifts the therapeutic focus from targeting DNA mutations to developing drugs, like IDH inhibitors, that correct these underlying control mechanisms.

Cellular senescence is a biological process that permanently halts cell division. Contrary to being just a sign of aging, its primary function is to prevent damaged cells from becoming cancerous. It's a protective measure that stops unchecked proliferation when a cell cannot repair its own damage or undergo programmed cell death.

Therapies that rewire cancer cells to mature can cause "differentiation syndrome," a flood of immune cells. While a dangerous side effect, it's considered an on-target toxicity, confirming the drug is successfully restoring the cell's lost function and providing a real-time signal of its effectiveness.